Barely Significant
← all excerpts

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.

Prostate Cancer · 2017 · PMC5735648 · PMID 29359049

Europe PMCDOI
1
hedged sentence
0.0200
closest p · 0.4× alpha
0.0200
boldest claim

The sentences

nominally significantp = 0.02actually significant
In the postdocetaxel setting, the advantage of enzalutamide use was nominally significant for median PFS (1.2 months p = 0.02 without adjustment and 2.2 months and p = 0.0007 after adjustment); there was no significant difference in median OS between the two agents.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.